Diseases /
Adenocarcinoma of the Gastroesophageal Junction
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: An adenocarcinoma that arises from and straddles the junction of the stomach and esophagus. The category of adenocarcinomas of the gastroesophageal junction also includes the majority of adenocarcinomas previously called gastric cardia adenocarcinomas. Squamous cell carcinomas that affect or cross the junction of the stomach and esophagus are classified as carcinomas of the distal esophagus. Adenocarcinoma of the gastroesophageal junction occurs more often in Caucasian middle aged and elderly males. Clinical signs and symptoms include dysphagia, abdominal pain, and weight loss. The prognosis depends on the completeness of the surgical resection, the number of lymph nodes involved by cancer, and the presence or absence of postoperative complications. The presence of TP53 mutations indicates worse prognosis. [1]
Adenocarcinoma of the gastroesophageal junctions most frequently harbor alterations in TP53, ERBB2, CDKN2A, ARID1A, and KRAS [2].
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, TP53 Exon 8 Mutation, and TP53 Exon 5 Mutation are the most common alterations in adenocarcinoma of the gastroesophageal junction [2].
Biomarker-Directed Therapies
Of the biomarker-directed therapies for adenocarcinoma of the gastroesophageal junction, 3 are FDA-approved in at least one setting and 2 have NCCN guidelines in at least one setting [3].
Fam-Trastuzumab Deruxtecan +
Disease is predicted to be sensitive: -
Trastuzumab +
Disease is predicted to be sensitive: -
Capecitabine + Cisplatin + Trastuzumab +
Cisplatin + Fluorouracil + Trastuzumab +
Pembrolizumab + Trastuzumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: Indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced, unresectable, or metastatic HER2+ gastric or GEJ adenocarcinoma. |
There are 243 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 197 are open and 46 are completed or closed. Of the trials that contain adenocarcinoma of the gastroesophageal junction as an inclusion criterion, 3 are early phase 1 (3 open), 68 are phase 1 (51 open), 52 are phase 1/phase 2 (45 open), 89 are phase 2 (73 open), 5 are phase 2/phase 3 (4 open), 25 are phase 3 (21 open), and 1 is no phase specified (0 open).
HER2, ERBB2, and PD-L1 are the most frequent gene inclusion criteria for adenocarcinoma of the gastroesophageal junction clinical trials [3].
Pembrolizumab, paclitaxel, and oxaliplatin are the most common interventions in adenocarcinoma of the gastroesophageal junction clinical trials.
Significant Genes in Adenocarcinoma of the Gastroesophageal Junction
ABL1 +
ABL1 is altered in 2.3% of adenocarcinoma of the gastroesophageal junction patients [2].
ABL1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
AKT1 +
AKT1 is altered in 0.56% of adenocarcinoma of the gastroesophageal junction patients [2].
AKT1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
ALK +
ALK is altered in 3.16% of adenocarcinoma of the gastroesophageal junction patients [2].
ALK is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 1 is closed. Of the trials that contain ALK status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (1 open) [3].
APC +
APC is altered in 7.93% of adenocarcinoma of the gastroesophageal junction patients [2].
APC is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains APC status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
ARID1A +
ARID1A is altered in 13.66% of adenocarcinoma of the gastroesophageal junction patients [2].
ARID1A is an inclusion eligibility criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain ARID1A status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
ATM +
ATM is altered in 5.26% of adenocarcinoma of the gastroesophageal junction patients [2].
ATM is an inclusion eligibility criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain ATM status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [3].
ATR +
ATR is altered in 1.3% of adenocarcinoma of the gastroesophageal junction patients [2].
ATR is an inclusion eligibility criterion in 6 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 5 are open and 1 is closed. Of the trials that contain ATR status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [3].
ATRX +
ATRX is altered in 2.52% of adenocarcinoma of the gastroesophageal junction patients [2].
ATRX is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain ATRX status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
BARD1 +
BARD1 is altered in 0.79% of adenocarcinoma of the gastroesophageal junction patients [2].
BARD1 is an inclusion eligibility criterion in 7 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 6 are open and 1 is closed. Of the trials that contain BARD1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [3].
BRAF +
BRAF is altered in 1.88% of adenocarcinoma of the gastroesophageal junction patients [2].
BRAF is an inclusion eligibility criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 3 are phase 2 (3 open) [3].
BRCA1 +
BRCA1 is altered in 2.16% of adenocarcinoma of the gastroesophageal junction patients [2].
BRCA1 is an inclusion eligibility criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain BRCA1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [3].
BRCA2 +
BRCA2 is altered in 4.89% of adenocarcinoma of the gastroesophageal junction patients [2].
BRCA2 is an inclusion eligibility criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain BRCA2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [3].
BRIP1 +
BRIP1 is altered in 1.94% of adenocarcinoma of the gastroesophageal junction patients [2].
BRIP1 is an inclusion eligibility criterion in 7 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 6 are open and 1 is closed. Of the trials that contain BRIP1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [3].
BTRC +
BTRC is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
C11ORF30 +
C11orf30 is altered in 0.6% of adenocarcinoma of the gastroesophageal junction patients [2].
C11orf30 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain C11orf30 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
CCND1 +
CCND1 is altered in 8.46% of adenocarcinoma of the gastroesophageal junction patients [2].
CCND1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
CDK12 +
CDK12 is altered in 11.97% of adenocarcinoma of the gastroesophageal junction patients [2].
CDK12 is an inclusion eligibility criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain CDK12 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [3].
CDK4 +
CDK4 is altered in 2.56% of adenocarcinoma of the gastroesophageal junction patients [2].
CDK4 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
CDK6 +
CDK6 is altered in 6.13% of adenocarcinoma of the gastroesophageal junction patients [2].
CDK6 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
CDKN2A +
CDKN2A is altered in 19.72% of adenocarcinoma of the gastroesophageal junction patients [2].
CDKN2A is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
CHEK1 +
CHEK1 is altered in 0.77% of adenocarcinoma of the gastroesophageal junction patients [2].
CHEK1 is an inclusion eligibility criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 1 is closed. Of the trials that contain CHEK1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [3].
CHEK2 +
CHEK2 is altered in 2.55% of adenocarcinoma of the gastroesophageal junction patients [2].
CHEK2 is an inclusion eligibility criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain CHEK2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [3].
CSF1R +
CSF1R is altered in 1.66% of adenocarcinoma of the gastroesophageal junction patients [2].
CSF1R is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
CTNNB1 +
CTNNB1 is altered in 4.84% of adenocarcinoma of the gastroesophageal junction patients [2].
CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
DDR2 +
DDR2 is altered in 2.17% of adenocarcinoma of the gastroesophageal junction patients [2].
DDR2 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
DDX3X +
DDX3X is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
DVL1 +
DVL1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
EGFR +
EGFR is altered in 5.0% of adenocarcinoma of the gastroesophageal junction patients [2].
EGFR is an inclusion eligibility criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 1 is closed. Of the trials that contain EGFR status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 3 are phase 2 (2 open) [3].
EPCAM +
EPCAM is altered in 1.79% of adenocarcinoma of the gastroesophageal junction patients [2].
EPCAM is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
EPHA2 +
EPHA2 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
ERBB2 +
ERBB2 is altered in 19.62% of adenocarcinoma of the gastroesophageal junction patients [2].
ERBB2 is an inclusion eligibility criterion in 42 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 32 are open and 10 are closed. Of the trials that contain ERBB2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 8 are phase 1 (6 open), 6 are phase 1/phase 2 (4 open), 19 are phase 2 (16 open), 4 are phase 2/phase 3 (3 open), and 5 are phase 3 (3 open) [3].
Capecitabine, cisplatin, trastuzumab, fluorouracil, fam-trastuzumab deruxtecan, and pembrolizumab have evidence of efficacy in patients with ERBB2 mutation in adenocarcinoma of the gastroesophageal junction [3].
ERBB3 +
ERBB3 is altered in 4.42% of adenocarcinoma of the gastroesophageal junction patients [2].
ERBB3 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain ERBB3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
ERBB4 +
ERBB4 is altered in 7.34% of adenocarcinoma of the gastroesophageal junction patients [2].
ERBB4 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
ERCC2 +
ERCC2 is altered in 2.1% of adenocarcinoma of the gastroesophageal junction patients [2].
ERCC2 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain ERCC2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
ERCC3 +
ERCC3 is altered in 1.09% of adenocarcinoma of the gastroesophageal junction patients [2].
ERCC3 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain ERCC3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
ERCC4 +
ERCC4 is altered in 3.97% of adenocarcinoma of the gastroesophageal junction patients [2].
ERCC4 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain ERCC4 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
ERCC5 +
ERCC5 is altered in 0.73% of adenocarcinoma of the gastroesophageal junction patients [2].
ERCC5 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain ERCC5 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
ERCC6 +
ERCC6 is altered in 0.63% of adenocarcinoma of the gastroesophageal junction patients [2].
ERCC6 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain ERCC6 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
EXO1 +
EXO1 is altered in 10.81% of adenocarcinoma of the gastroesophageal junction patients [2].
EXO1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCA +
FANCA is altered in 2.51% of adenocarcinoma of the gastroesophageal junction patients [2].
FANCA is an inclusion eligibility criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain FANCA status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [3].
FANCB +
FANCB is altered in 2.7% of adenocarcinoma of the gastroesophageal junction patients [2].
FANCB is an inclusion eligibility criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 1 is closed. Of the trials that contain FANCB status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [3].
FANCC +
FANCC is altered in 0.96% of adenocarcinoma of the gastroesophageal junction patients [2].
FANCC is an inclusion eligibility criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 1 is closed. Of the trials that contain FANCC status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [3].
FANCD2 +
FANCD2 is altered in 1.43% of adenocarcinoma of the gastroesophageal junction patients [2].
FANCD2 is an inclusion eligibility criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 1 is closed. Of the trials that contain FANCD2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [3].
FANCE +
FANCE is altered in 1.47% of adenocarcinoma of the gastroesophageal junction patients [2].
FANCE is an inclusion eligibility criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 1 is closed. Of the trials that contain FANCE status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [3].
FANCF +
FANCF is altered in 0.74% of adenocarcinoma of the gastroesophageal junction patients [2].
FANCF is an inclusion eligibility criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 1 is closed. Of the trials that contain FANCF status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [3].
FANCG +
FANCG is altered in 1.45% of adenocarcinoma of the gastroesophageal junction patients [2].
FANCG is an inclusion eligibility criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 1 is closed. Of the trials that contain FANCG status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [3].
FANCI +
FANCI is an inclusion eligibility criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 1 is closed. Of the trials that contain FANCI status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [3].
FANCL +
FANCL is altered in 3.75% of adenocarcinoma of the gastroesophageal junction patients [2].
FANCL is an inclusion eligibility criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 1 is closed. Of the trials that contain FANCL status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [3].
FANCM +
FANCM is altered in 10.81% of adenocarcinoma of the gastroesophageal junction patients [2].
FANCM is an inclusion eligibility criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 1 is closed. Of the trials that contain FANCM status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [3].
FGFR1 +
FGFR1 is altered in 2.89% of adenocarcinoma of the gastroesophageal junction patients [2].
FGFR1 is an inclusion eligibility criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 5 are open and 0 are closed. Of the trials that contain FGFR1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 4 are phase 2 (4 open) [3].
FGFR2 +
FGFR2 is altered in 3.63% of adenocarcinoma of the gastroesophageal junction patients [2].
FGFR2 is an inclusion eligibility criterion in 7 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 6 are open and 1 is closed. Of the trials that contain FGFR2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 6 are phase 2 (5 open) [3].
FGFR3 +
FGFR3 is altered in 1.39% of adenocarcinoma of the gastroesophageal junction patients [2].
FGFR3 is an inclusion eligibility criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain FGFR3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
FGFR4 +
FGFR4 is altered in 1.2% of adenocarcinoma of the gastroesophageal junction patients [2].
FGFR4 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
FLT1 +
FLT1 is altered in 2.86% of adenocarcinoma of the gastroesophageal junction patients [2].
FLT1 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain FLT1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (2 open) [3].
FLT3 +
FLT3 is altered in 1.13% of adenocarcinoma of the gastroesophageal junction patients [2].
FLT3 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
FLT4 +
FLT4 is altered in 3.88% of adenocarcinoma of the gastroesophageal junction patients [2].
FLT4 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain FLT4 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (2 open) [3].
FRK +
FRK is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains FRK status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
FZD1 +
FZD1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD10 +
FZD10 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD2 +
FZD2 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD3 +
FZD3 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD4 +
FZD4 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD5 +
FZD5 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD6 +
FZD6 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD7 +
FZD7 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD8 +
FZD8 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD9 +
FZD9 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
GEN1 +
GEN1 is altered in 2.7% of adenocarcinoma of the gastroesophageal junction patients [2].
GEN1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains GEN1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
HDAC1 +
HDAC1 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain HDAC1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain HDAC2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
KDR +
KDR is altered in 1.98% of adenocarcinoma of the gastroesophageal junction patients [2].
KDR is an inclusion eligibility criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 1 is closed. Of the trials that contain KDR status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 3 are phase 2 (2 open) [3].
KIT +
KIT is altered in 1.41% of adenocarcinoma of the gastroesophageal junction patients [2].
KIT is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain KIT status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (2 open) [3].
KMT2D +
KMT2D is altered in 7.69% of adenocarcinoma of the gastroesophageal junction patients [2].
KMT2D is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
KRAS +
KRAS is altered in 11.42% of adenocarcinoma of the gastroesophageal junction patients [2].
KRAS is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 2 are closed. Of the trials that contain KRAS status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (0 open) [3].
LRP5 +
LRP5 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
LRP6 +
LRP6 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains LRP6 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
MAPK11 +
MAPK11 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 4 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 1 is closed. Of the trials that contain MCPH1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (3 open) [3].
MDM2 +
MDM2 is altered in 7.59% of adenocarcinoma of the gastroesophageal junction patients [2].
MDM2 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain MDM2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MDM4 +
MDM4 is altered in 0.32% of adenocarcinoma of the gastroesophageal junction patients [2].
MDM4 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MET +
MET is altered in 4.29% of adenocarcinoma of the gastroesophageal junction patients [2].
MET is an inclusion eligibility criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 1 is closed. Of the trials that contain MET status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain MLF1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MLH1 +
MLH1 is altered in 0.58% of adenocarcinoma of the gastroesophageal junction patients [2].
MLH1 is an inclusion eligibility criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain MLH1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
MLH3 +
MLH3 is an inclusion eligibility criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain MLH3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
MRE11A +
MRE11A is altered in 2.29% of adenocarcinoma of the gastroesophageal junction patients [2].
MRE11A is an inclusion eligibility criterion in 6 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 5 are open and 1 is closed. Of the trials that contain MRE11A status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [3].
MSH2 +
MSH2 is altered in 1.86% of adenocarcinoma of the gastroesophageal junction patients [2].
MSH2 is an inclusion eligibility criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain MSH2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
MSH3 +
MSH3 is altered in 3.08% of adenocarcinoma of the gastroesophageal junction patients [2].
MSH3 is an inclusion eligibility criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain MSH3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
MSH6 +
MSH6 is altered in 3.42% of adenocarcinoma of the gastroesophageal junction patients [2].
MSH6 is an inclusion eligibility criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain MSH6 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
MST1R +
MST1R is altered in 2.52% of adenocarcinoma of the gastroesophageal junction patients [2].
MST1R is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains MST1R status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
MTAP +
MTAP is altered in 1.06% of adenocarcinoma of the gastroesophageal junction patients [2].
MTAP is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains MTAP status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
MTOR +
MTOR is altered in 3.6% of adenocarcinoma of the gastroesophageal junction patients [2].
MTOR is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
MUTYH +
MUTYH is altered in 0.32% of adenocarcinoma of the gastroesophageal junction patients [2].
MUTYH is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain MUTYH status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MYC +
MYC is altered in 8.92% of adenocarcinoma of the gastroesophageal junction patients [2].
MYC is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains MYC status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
NBN +
NBN is altered in 0.69% of adenocarcinoma of the gastroesophageal junction patients [2].
NBN is an inclusion eligibility criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain NBN status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [3].
NPM1 +
NPM1 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
NRAS +
NRAS is altered in 1.12% of adenocarcinoma of the gastroesophageal junction patients [2].
NRAS is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (0 open) [3].
NRG1 +
NRG1 is altered in 2.58% of adenocarcinoma of the gastroesophageal junction patients [2].
NRG1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains NRG1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
NTRK1 +
NTRK1 is altered in 1.89% of adenocarcinoma of the gastroesophageal junction patients [2].
NTRK1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
NTRK2 +
NTRK2 is altered in 1.9% of adenocarcinoma of the gastroesophageal junction patients [2].
NTRK2 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
NTRK3 +
NTRK3 is altered in 3.13% of adenocarcinoma of the gastroesophageal junction patients [2].
NTRK3 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
PALB2 +
PALB2 is altered in 2.8% of adenocarcinoma of the gastroesophageal junction patients [2].
PALB2 is an inclusion eligibility criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain PALB2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [3].
PARP1 +
PARP1 is altered in 0.55% of adenocarcinoma of the gastroesophageal junction patients [2].
PARP1 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain PARP1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
PARP2 +
PARP2 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain PARP2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
PCNA +
PCNA is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
PDGFRA +
PDGFRA is altered in 1.68% of adenocarcinoma of the gastroesophageal junction patients [2].
PDGFRA is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (2 open) [3].
PDGFRB +
PDGFRB is altered in 1.91% of adenocarcinoma of the gastroesophageal junction patients [2].
PDGFRB is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain PDGFRB status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (2 open) [3].
PIK3CA +
PIK3CA is altered in 7.49% of adenocarcinoma of the gastroesophageal junction patients [2].
PIK3CA is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 1 is closed. Of the trials that contain PIK3CA status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (1 open) [3].
PMS1 +
PMS1 is altered in 2.49% of adenocarcinoma of the gastroesophageal junction patients [2].
PMS1 is an inclusion eligibility criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain PMS1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
PMS2 +
PMS2 is altered in 2.3% of adenocarcinoma of the gastroesophageal junction patients [2].
PMS2 is an inclusion eligibility criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain PMS2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
POLD1 +
POLD1 is altered in 3.48% of adenocarcinoma of the gastroesophageal junction patients [2].
POLD1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
POLE +
POLE is altered in 3.56% of adenocarcinoma of the gastroesophageal junction patients [2].
POLE is an inclusion eligibility criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain POLE status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
PPP2R1A +
PPP2R1A is altered in 1.48% of adenocarcinoma of the gastroesophageal junction patients [2].
PPP2R1A is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain PPP2R1A status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
PPP2R2A +
PPP2R2A is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain PPP2R2A status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
PTEN +
PTEN is altered in 4.16% of adenocarcinoma of the gastroesophageal junction patients [2].
PTEN is an inclusion eligibility criterion in 4 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 1 is closed. Of the trials that contain PTEN status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (3 open) [3].
RAD50 +
RAD50 is altered in 1.14% of adenocarcinoma of the gastroesophageal junction patients [2].
RAD50 is an inclusion eligibility criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 1 is closed. Of the trials that contain RAD50 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [3].
RAD51 +
RAD51 is an inclusion eligibility criterion in 7 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 6 are open and 1 is closed. Of the trials that contain RAD51 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [3].
RAD51B +
RAD51B is altered in 0.39% of adenocarcinoma of the gastroesophageal junction patients [2].
RAD51B is an inclusion eligibility criterion in 6 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 5 are open and 1 is closed. Of the trials that contain RAD51B status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [3].
RAD51C +
RAD51C is altered in 1.3% of adenocarcinoma of the gastroesophageal junction patients [2].
RAD51C is an inclusion eligibility criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain RAD51C status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [3].
RAD51D +
RAD51D is altered in 1.76% of adenocarcinoma of the gastroesophageal junction patients [2].
RAD51D is an inclusion eligibility criterion in 7 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 6 are open and 1 is closed. Of the trials that contain RAD51D status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [3].
RAD54L +
RAD54L is altered in 0.57% of adenocarcinoma of the gastroesophageal junction patients [2].
RAD54L is an inclusion eligibility criterion in 7 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 6 are open and 1 is closed. Of the trials that contain RAD54L status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [3].
RAF1 +
RAF1 is altered in 1.27% of adenocarcinoma of the gastroesophageal junction patients [2].
RAF1 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain RAF1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (2 open) [3].
RET +
RET is altered in 2.78% of adenocarcinoma of the gastroesophageal junction patients [2].
RET is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain RET status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (2 open) [3].
RFC1 +
RFC1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC2 +
RFC2 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC3 +
RFC3 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC4 +
RFC4 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC5 +
RFC5 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
ROS1 +
ROS1 is altered in 4.43% of adenocarcinoma of the gastroesophageal junction patients [2].
ROS1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA1 +
RPA1 is altered in 2.7% of adenocarcinoma of the gastroesophageal junction patients [2].
RPA1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains RPA1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA2 +
RPA2 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA3 +
RPA3 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA4 +
RPA4 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
SLX4 +
SLX4 is altered in 1.81% of adenocarcinoma of the gastroesophageal junction patients [2].
SLX4 is an inclusion eligibility criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 1 is closed. Of the trials that contain SLX4 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [3].
SMARCA4 +
SMARCA4 is altered in 6.85% of adenocarcinoma of the gastroesophageal junction patients [2].
SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
SMARCB1 +
SMARCB1 is altered in 0.86% of adenocarcinoma of the gastroesophageal junction patients [2].
SMARCB1 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
SSBP1 +
SSBP1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
STAG2 +
STAG2 is altered in 0.96% of adenocarcinoma of the gastroesophageal junction patients [2].
STAG2 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain STAG2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
STK11 +
STK11 is altered in 3.31% of adenocarcinoma of the gastroesophageal junction patients [2].
STK11 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain STK11 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
TEK +
TEK is altered in 1.97% of adenocarcinoma of the gastroesophageal junction patients [2].
TEK is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains TEK status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
TP53 +
TP53 is altered in 70.7% of adenocarcinoma of the gastroesophageal junction patients [2].
TP53 is an inclusion eligibility criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 2 are closed. Of the trials that contain TP53 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (1 open) [3].
TRNAK2 +
TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
TSC1 +
TSC1 is altered in 1.48% of adenocarcinoma of the gastroesophageal junction patients [2].
TSC1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
TSC2 +
TSC2 is altered in 3.05% of adenocarcinoma of the gastroesophageal junction patients [2].
TSC2 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
VEGFA +
VEGFA is altered in 6.14% of adenocarcinoma of the gastroesophageal junction patients [2].
VEGFA is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
VEGFB +
VEGFB is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
VEGFC +
VEGFC is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
VHL +
VHL is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains VHL status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [3].
WNT1 +
WNT1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains WNT1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [3].
XRCC1 +
XRCC1 is an inclusion eligibility criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain XRCC1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
